Revvity Inc. (RVTY)
RVTY trades on NYSE in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-28, https://www.sec.gov/Archives/edgar/data/31791/000003179126000012/0000031791-26-000012-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-28.
Profile
| Field | Value |
|---|---|
| Ticker | RVTY on NYSE |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000031791 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | MA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.9B |
| Net income | $241.2M |
| Operating income | $356.6M |
| Net margin | 8.4% |
| Operating margin | 12.5% |
| Revenue growth | +3.7% |
| Cash | $919.9M |
| Total assets | $12.2B |
| P/E (computed) | 68.9× |
| P/S (computed) | 5.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $592.8M cash; operating cash flow $164.0M a quarter. | Report 2026-10-04 |
| Shares outstanding | 111,638,757 (2026-11-06); 113,375,621 a year earlier; 123,407,288 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-07-20 |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $6.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-10-04 | $728.9M | $62.3M | $166.7M | $592.8M | $2.6B | $2.9B | 10-Q 2026-11-10 |
| Q2 2026 2026-07-05 | $729.7M | $51.8M | $191.9M | $1.0B | $3.2B | $2.9B | 10-Q 2026-08-11 |
| Q1 2026 2026-04-05 | $711.1M | $40.7M | $115.2M | $860.3M | $3.2B | $2.9B | 10-Q 2026-05-12 |
| Q4 2025 2025-12-28 | $772.1M | $98.4M | $182.0M | $919.9M | $3.2B | $2.9B | 10-K 2026-02-24 |
| Q3 2025 2025-09-28 | $698.9M | $46.7M | $138.5M | $931.4M | $3.2B | $2.8B | 10-Q 2026-11-10 |
| Q2 2025 2025-06-29 | $720.3M | $53.9M | $134.3M | $991.8M | $3.2B | $2.8B | 10-Q 2026-08-11 |
| Q1 2025 2025-03-30 | $664.8M | $42.2M | $128.2M | $1.1B | $3.2B | $2.8B | 10-Q 2026-05-12 |
| Q4 2024 2024-12-29 | $729.4M | $94.6M | $174.2M | $1.2B | $3.2B | $2.8B | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2025-02-28 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-03-16 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.5% |
| 1 month | -0.4% |
| 3 months | +31.4% |
| Year to date | +59.6% |
| 1 year | +65.3% |
| From 52-week high | -6.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AVTR | Avantor Inc. | $15.32 | -1.42% | $10.4B |
| BIO | Bio-Rad Laboratories Inc. | $360.26 | -1.67% | $9.7B |
| BRKR | Bruker Corporation | $60.62 | -1.57% | $9.3B |
| MTD | Mettler-Toledo International Inc. | $1727.26 | -0.67% | $34.4B |
| TXG | 10x Genomics Inc. | $54.99 | -5.50% | $7.2B |
| WAT | Waters Corporation | $453.42 | -1.48% | $44.6B |
| A | Agilent Technologies Inc. | $172.92 | -0.60% | $48.8B |
| ALMR | Alamar Biosciences Inc. | $30.55 | -0.84% | $2.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier